Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Laboratorio Chile Estimates US$225 Million the Savings of the Treasury with Sale of the Generic Counterpart of the Ozempic

Summary by La Tercera
According to a laboratory presentation, the state would save an estimated US$ 225 million by allowing generic semaglutide (Selfix) to be marketed. This savings is due to the reduction in the cost per patient versus the use of the original Ozempic drug, which would reduce the total disbursement of the system from US$ 374 million to US$ 150 million.

1 Articles

La TerceraLa Tercera
Lean Right

Laboratorio Chile Estimates US$225 Million the Savings of the Treasury with Sale of the Generic Counterpart of the Ozempic

According to a laboratory presentation, the state would save an estimated US$ 225 million by allowing generic semaglutide (Selfix) to be marketed. This savings is due to the reduction in the cost per patient versus the use of the original Ozempic drug, which would reduce the total disbursement of the system from US$ 374 million to US$ 150 million.

·Las Condes, Chile
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

La Tercera broke the news in Las Condes, Chile on Thursday, August 20, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

GLP-1 icon

GLP-1

Ozempic icon

Ozempic

Chile icon

Chile

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal